In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice

Hdl Handle:
http://hdl.handle.net/10147/279593
Title:
In vivo activity of Nisin A and Nisin V against Listeria monocytogenes in mice
Authors:
Campion, Alicia; Casey, Pat G; Field, Des; Cotter, Paul D; Hill, Colin; Ross, R Paul
Citation:
BMC Microbiology. 2013 Feb 01;13(1):23
Issue Date:
1-Feb-2013
URI:
http://dx.doi.org/10.1186/1471-2180-13-23; http://hdl.handle.net/10147/279593
Abstract:
Abstract Background Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo. Results Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model. More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 × 105 cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen. Conclusion This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.
Item Type:
Article
Keywords:
INFECTION CONTROL

Full metadata record

DC FieldValue Language
dc.contributor.authorCampion, Aliciaen_GB
dc.contributor.authorCasey, Pat Gen_GB
dc.contributor.authorField, Desen_GB
dc.contributor.authorCotter, Paul Den_GB
dc.contributor.authorHill, Colinen_GB
dc.contributor.authorRoss, R Paulen_GB
dc.date.accessioned2013-04-10T12:17:58Z-
dc.date.available2013-04-10T12:17:58Z-
dc.date.issued2013-02-01-
dc.identifier.citationBMC Microbiology. 2013 Feb 01;13(1):23en_GB
dc.identifier.urihttp://dx.doi.org/10.1186/1471-2180-13-23-
dc.identifier.urihttp://hdl.handle.net/10147/279593-
dc.description.abstractAbstract Background Lantibiotics are post-translationally modified antimicrobial peptides, of which nisin A is the most extensively studied example. Bioengineering of nisin A has resulted in the generation of derivatives with increased in vitro potency against Gram-positive bacteria. Of these, nisin V (containing a Met21Val change) is noteworthy by virtue of exhibiting enhanced antimicrobial efficacy against a wide range of clinical and food-borne pathogens, including Listeria monocytogenes. However, this increased potency has not been tested in vivo. Results Here we address this issue by assessing the ability of nisin A and nisin V to control a bioluminescent strain of Listeria monocytogenes EGDe in a murine infection model. More specifically, Balb/c mice were infected via the intraperitoneal route at a dose of 1 × 105 cfu/animal and subsequently treated intraperitoneally with either nisin V, nisin A or a PBS control. Bioimaging of the mice was carried out on day 3 of the trial. Animals were then sacrificed and levels of infection were quantified in the liver and spleen. Conclusion This analysis revealed that nisin V was more effective than Nisin A with respect to controlling infection and therefore merits further investigation with a view to potential chemotherapeutic applications.-
dc.subjectINFECTION CONTROLen_GB
dc.titleIn vivo activity of Nisin A and Nisin V against Listeria monocytogenes in miceen_GB
dc.typeArticleen
dc.language.rfc3066en-
dc.rights.holderAlicia Campion et al.; licensee BioMed Central Ltd.-
dc.description.statusPeer Reviewed-
dc.date.updated2013-04-04T19:03:28Z-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.